CareDx, Inc.: management transactions · United States · SEC (Form 4)

About CareDx, Inc.

CareDx, Inc. (ticker: CDNA) is a U.S.-based precision medicine company listed on the NASDAQ in the United States, focused on improving outcomes for transplant patients. Its business model is built around transplant diagnostics, laboratory products, digital health tools, and patient support services. In practical terms, CareDx aims to provide clinicians, transplant centers, and patients with better visibility across the transplant journey, especially in the post-transplant monitoring phase. The company’s headquarters is in Brisbane, California, with additional primary operations in Omaha, Nebraska, and Stockholm, Sweden. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1217234/000121723426000018/cdna-20251231.htm?utm_source=openai)) Founded in 2000, CareDx has evolved from a diagnostics-focused company into a broader transplant solutions platform. Its commercially available testing portfolio includes AlloSure Kidney, AlloMap Heart, AlloSure Heart, HeartCare, and AlloSure Lung, which are used in monitoring kidney, heart, and lung transplant recipients. Beyond these molecular tests, the company offers digital health solutions and patient services designed to improve care coordination, workflow efficiency, and the patient experience. This integrated approach is important in a specialized market where clinical evidence, reimbursement, and physician adoption are key competitive drivers. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1217234/000121723426000018/cdna-20251231.htm?utm_source=openai)) From a competitive standpoint, CareDx operates in a niche but strategically attractive segment of healthcare. The transplant monitoring market is shaped by the need for non-invasive, clinically validated tools and strong relationships with transplant centers. CareDx differentiates itself by combining molecular diagnostics with digital capabilities, rather than relying on a single-product model. Its geographic footprint is concentrated in North America and Europe through operations and commercial infrastructure, while its customer base spans transplant programs and healthcare stakeholders. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1217234/000121723426000018/cdna-20251231.htm?utm_source=openai)) Recent developments are notable for investors. CareDx reported full-year 2025 revenue of $380 million, up 14% year over year, supported by growth in testing services, patient and digital solutions, and product revenue. In April 2026, the company announced an agreement to sell the shares of its Swedish subsidiary CareDx AB and certain assets related to its kitted laboratory products business to Eurobio Scientific for $170 million in cash, suggesting a possible portfolio simplification and greater focus on core transplant diagnostics and digital offerings. For French-speaking investors, CDNA is therefore a U.S.-listed NASDAQ healthcare name with a specialized transplant franchise, a global operating footprint, and a recent strategic step that may reshape its business mix. ([investors.caredx.com](https://investors.caredx.com/news/news-details/2026/CareDx-Announces-Fourth-Quarter-and-Full-Year-2025-Financial-Results?utm_source=openai))